COMMUNIQUÉS West-GlobeNewswire

Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
20/10/2025
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a [...]
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
20/10/2025
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data 1,2 Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a [...]
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
20/10/2025
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo 1 IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guided approach to [...]
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
20/10/2025
Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at the American College [...]
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
20/10/2025
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS [...]
Communiqué de presse : ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines (...)
20/10/2025
ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines gastro- [...]
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20/10/2025
ESMO: AlphaMedix TM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically meaningful responses [...]
Communiqué de presse : ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines (...)
20/10/2025
ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines gastro- [...]
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20/10/2025
ESMO: AlphaMedix TM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically meaningful responses [...]
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
20/10/2025
Activity Report for Quarter Ended September 30, 2025 (Appendix 4C) NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory [...]
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
19/10/2025
Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91% [...]
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
19/10/2025
Pluvicto TM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-sensitive prostate [...]
Subcutaneous RYBREVANT®▼(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
19/10/2025
Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients 1 New findings from this investigational study build on the strength of the data for amivantamab in non-small cell lung [...]
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
19/10/2025
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a [...]
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
19/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing [...]
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
18/10/2025
Study data also showed prolonged progression-free survival with 177 Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading [...]
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
18/10/2025
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S ® ) 100 mg/m 2 demonstrated 50% confirmed objective response rate (ORR), [...]
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
18/10/2025
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival of approximately 12 months for patients with extensive-stage disease Precede Bio’s platform [...]
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
18/10/2025
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer (mCRPC) No dose-limiting [...]

Pages